12:24 AM EDT, 10/26/2026 (MT Newswires) -- Orion's (ORNAV.HE, ORNBV.HE) prostate cancer treatment darolutamide reduced the risk of spread of cancer cells or death by 58% in patients with high-risk prostate cancer when added to standard-of-care androgen deprivation therapy and locoregional radiation therapy, the company said. The DASL-HiCaP phase 3 trial showed a four-year metastasis-free survival rate of 95% with darolutamide against 88% with placebo, according to the Finnish pharmaceutical group's Oct. 24 release. Orion said the treatment's safety profile was consistent with previous studies, although higher adverse events occurred in 43% of patients receiving darolutamide, compared with 36% in the placebo group.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.